On May 1, 2025, Nektar Therapeutics (Nasdaq: NKTR) disclosed that they are set to unveil their first-quarter financial outcomes on May 8, 2025, post the closure of U.S. financial markets. Howard Robin, the President, and Chief Executive Officer, will lead a conference to discuss these results.